CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 140 enrolled
Drug / intervention
Probioticdietary
Likely dose
Not stated in record
Key inclusion· 5
  • Woman aged 18–50 years old
  • BMI ≥18 at screening
  • Currently on antibiotic treatment for UTI at screening, with treatment stopping within 3 days prior to first study drug dose
  • Recurrent UTI documented as ≥2 UTIs in last 6 months OR ≥3 UTIs in last 12 months
Key exclusion· 8
  • Postmenopausal (≥12 months amenorrhea)
  • Pregnant or breastfeeding
  • Planning to become pregnant during study
  • Irregular menstruations with perimenopausal symptoms

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03366077
NCT03366077N/ACompleted

A Double-blinded, Randomized, Placebo-controlled, Parallel-group Study Evaluating the Effect of the Probiotic on Recurrent Urinary Tract Infection (UTI) in Adult Women Recently Treated for UTI.

BioGaia AB·interventional·Posted Dec 8, 2017·Updated Sep 15, 2025

In Brief

A clinical study evaluating Probiotic for Recurrent Urinary Tract Infection in Adult Women. Completed, enrolled 140 participants across 1 site.

Detailed Summary

Urinary tract infections (UTIs) are the most common bacterial infections in women, with about 50% of women experiencing at least one UTI in their lifetime. The main pharmacological treatments of cystitis usually involve the use of antibiotics, in particular quinolones (such as ciprofloxacin and levofloxacin), fosfomycin, second-generation and third-generation cephalosporins, and b-lactam antibiotics associated with b-lactamase inhibitors.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesSweden
Collaborators--

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedDec 8, 2017
Enrollment StartDec 13, 2017
Primary CompletionJul 12, 2019
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 8.6 years ago

Interventions

Probioticdietary

Probiotic